These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34888886)

  • 1. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
    Seervai RNH; Heberton M; Cho WC; Gill P; Murphy MB; Aung PP; Nagarajan P; Torres-Cabala CA; Patel AB; Ruiz-Bañobre J; Om A; Yamamoto T; Nikolaou V; Curry JL
    J Cutan Pathol; 2022 May; 49(5):472-481. PubMed ID: 34888886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
    Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
    J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
    Okiyama N; Tanaka R
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer.
    Goel AR; Sylvester C; Avidan OR; Gilvaz VJ
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39097324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report.
    Norwood TG; Wang MJ; Huh WK
    Gynecol Oncol Rep; 2019 Nov; 30():100508. PubMed ID: 31737773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generalized pustular psoriasis induced by systemic steroid dose reduction.
    Westphal DC; Schettini AP; Souza PP; Castiel J; Chirano CA; Santos M
    An Bras Dermatol; 2016; 91(5):664-666. PubMed ID: 27828647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
    Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
    Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma.
    Di Altobrando A; Bruni F; Alessandrini A; Starace M; Misciali C; Piraccini BM
    Dermatol Ther; 2020 May; 33(3):e13363. PubMed ID: 32239596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
    Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.
    C Guven D; Kilickap S; Guner G; Taban H; Dizdar O
    J Oncol Pharm Pract; 2020 Jan; 26(1):256-258. PubMed ID: 31566114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology.
    Curry JL; Chon SY; Marques-Piubelli ML; Chu EY
    Surg Pathol Clin; 2021 Jun; 14(2):209-224. PubMed ID: 34023101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.
    Johnson D; Patel AB; Uemura MI; Trinh VA; Jackson N; Zobniw CM; Tetzlaff MT; Hwu P; Curry JL; Diab A
    Cancer Immunol Res; 2019 Jun; 7(6):860-865. PubMed ID: 30996018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
    Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
    Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.
    Jfri A; Leung B; Said JT; Semenov Y; LeBoeuf NR
    Immunother Adv; 2022; 2(1):ltac016. PubMed ID: 36196370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.